These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Treatment outcome of high-dose image-guided intensity-modulated radiotherapy using intra-prostate fiducial markers for localized prostate cancer at a single institute in Japan. Takeda K; Takai Y; Narazaki K; Mitsuya M; Umezawa R; Kadoya N; Fujita Y; Sugawara T; Kubozono M; Shimizu E; Abe K; Shirata Y; Ishikawa Y; Yamamoto T; Kozumi M; Dobashi S; Matsushita H; Chida K; Ishidoya S; Arai Y; Jingu K; Yamada S Radiat Oncol; 2012 Jul; 7():105. PubMed ID: 22770471 [TBL] [Abstract][Full Text] [Related]
7. Twice-weekly hypofractionated intensity-modulated radiotherapy for localized prostate cancer with low-risk nodal involvement: toxicity and outcome from a dose escalation pilot study. Zilli T; Jorcano S; Rouzaud M; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escudé L; Mollà M; Linero D; Weber DC; Miralbell R Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):382-9. PubMed ID: 20884129 [TBL] [Abstract][Full Text] [Related]
8. Outcome and toxicity for patients treated with intensity modulated radiation therapy for localized prostate cancer. Vora SA; Wong WW; Schild SE; Ezzell GA; Andrews PE; Ferrigni RG; Swanson SK J Urol; 2013 Aug; 190(2):521-6. PubMed ID: 23415964 [TBL] [Abstract][Full Text] [Related]
9. Intensity-modulated radiotherapy with simultaneous integrated boost to dominant intraprostatic lesion: preliminary report on toxicity. Ippolito E; Mantini G; Morganti AG; Mazzeo E; Padula GD; Digesù C; Cilla S; Frascino V; Luzi S; Massaccesi M; Macchia G; Deodato F; Mattiucci GC; Piermattei A; Cellini N Am J Clin Oncol; 2012 Apr; 35(2):158-62. PubMed ID: 21336090 [TBL] [Abstract][Full Text] [Related]
10. Acute toxicity in high-risk prostate cancer patients treated with androgen suppression and hypofractionated intensity-modulated radiotherapy. Pervez N; Small C; MacKenzie M; Yee D; Parliament M; Ghosh S; Mihai A; Amanie J; Murtha A; Field C; Murray D; Fallone G; Pearcey R Int J Radiat Oncol Biol Phys; 2010 Jan; 76(1):57-64. PubMed ID: 19395192 [TBL] [Abstract][Full Text] [Related]
11. Moderate Hypofractionated Postprostatectomy Volumetric Modulated Arc Therapy With Daily Image Guidance (VMAT-IGRT): A Mono-institutional Report on Feasibility and Acute Toxicity. Fersino S; Tebano U; Mazzola R; Giaj-Levra N; Ricchetti F; Di Paola G; Fiorentino A; Sicignano G; Naccarato S; Ruggieri R; Cavalleri S; Alongi F Clin Genitourin Cancer; 2017 Aug; 15(4):e667-e673. PubMed ID: 28237181 [TBL] [Abstract][Full Text] [Related]
12. Biochemical control and toxicity after intensity-modulated radiation therapy for prostate cancer. Liauw SL; Weichselbaum RR; Rash C; Correa D; Al-Hallaq HA; Pelizzari CA; Jani AB Technol Cancer Res Treat; 2009 Jun; 8(3):201-6. PubMed ID: 19445537 [TBL] [Abstract][Full Text] [Related]
13. Dose escalation study with two different hypofractionated intensity modulated radiotherapy techniques for localized prostate cancer: acute toxicity. Zilli T; Rouzaud M; Jorcano S; Dipasquale G; Nouet P; Toscas JI; Casanova N; Wang H; Escude L; Molla M; Linero D; Weber DC; Miralbell R Technol Cancer Res Treat; 2010 Jun; 9(3):263-70. PubMed ID: 20441236 [TBL] [Abstract][Full Text] [Related]
14. Moderate Hypofractionated Protracted Radiation Therapy and Dose Escalation for Prostate Cancer: Do Dose and Overall Treatment Time Matter? Kountouri M; Zilli T; Rouzaud M; Dubouloz A; Linero D; Escudé L; Jorcano S; Miralbell R Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):272-9. PubMed ID: 26853336 [TBL] [Abstract][Full Text] [Related]